Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
NCT05956821
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Fibrillary Astrocytomas
- Oligodendroglioma
- Diffuse Intrinsic Brainstem Glioma
- Diffuse Intrinsic Pontine Glioma
- DIPG Brain Tumor
- H3 K27M
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 1 year to 21 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Miami
- Last updated on ClinicalTrials.gov
- December 8, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Jackson Memorial Hospital · Miami, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.